Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
03
10
2022
accepted:
24
03
2023
revised:
22
03
2023
medline:
8
6
2023
pubmed:
9
4
2023
entrez:
8
4
2023
Statut:
ppublish
Résumé
Neddylation is a sequential enzyme-based process which regulates the function of E3 Cullin-RING ligase (CRL) and thus degradation of substrate proteins. Here we show that CD8
Identifiants
pubmed: 37031300
doi: 10.1038/s41375-023-01889-x
pii: 10.1038/s41375-023-01889-x
pmc: PMC10244170
doi:
Substances chimiques
pevonedistat
S3AZD8D215
Antineoplastic Agents
0
Cyclopentanes
0
NEDD8 Protein
0
UBE2M protein, human
EC 6.3.2.-
Ubiquitin-Conjugating Enzymes
EC 2.3.2.23
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1324-1335Subventions
Organisme : NCI NIH HHS
ID : R01 CA244576
Pays : United States
Organisme : LLS
ID : 2319-19
Pays : United States
Organisme : NCI NIH HHS
ID : 1R01CA244576
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220–31.
pubmed: 36507690
doi: 10.1056/NEJMoa2206913
Kersh AE, Ng S, Chang YM, Sasaki M, Thomas SN, Kissick HT, et al. Targeted therapies: immunologic effects and potential applications outside of cancer. J Clin Pharmacol. 2018;58:7–24.
pubmed: 29136276
doi: 10.1002/jcph.1028
Maharaj K, Sahakian E, Pinilla-Ibarz J. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia. Blood Adv. 2017;1:1867–75.
pubmed: 29296833
pmcid: 5728096
doi: 10.1182/bloodadvances.2017006809
Lam V, Best S, Kittai A, Orand K, Spurgeon SE, Liu T, et al. Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol. 2022;88:836–41.
pubmed: 34196037
doi: 10.1111/bcp.14962
Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Investig. 2008;118:2427–37.
pubmed: 18551193
pmcid: 2423865
Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood. 2013;121:2704–14.
pubmed: 23325833
pmcid: 3617635
doi: 10.1182/blood-2012-08-448332
Damgaard RB. The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities. Cell Death Differ. 2021;28:423–6.
pubmed: 33446876
pmcid: 7862391
doi: 10.1038/s41418-020-00703-w
Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6:9–20.
pubmed: 15688063
doi: 10.1038/nrm1547
Watson IR, Irwin MS, Ohh M. NEDD8 pathways in cancer, Sine Quibus Non. Cancer Cell. 2011;19:168–76.
pubmed: 21316600
doi: 10.1016/j.ccr.2011.01.002
Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732–6.
pubmed: 19360080
doi: 10.1038/nature07884
Shah JJ, Jakubowiak AJ, O’Connor OA, Orlowski RZ, Harvey RD, Smith MR, et al. Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma. Clin Cancer Res. 2016;22:34–43.
pubmed: 26561559
doi: 10.1158/1078-0432.CCR-15-1237
Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, et al. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol. 2015;169:534–43.
pubmed: 25733005
doi: 10.1111/bjh.13323
Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood. 2010;116:1515–23.
pubmed: 20525923
doi: 10.1182/blood-2010-03-272567
Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, et al. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-kappaB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014;20:1576–89.
pubmed: 24634471
pmcid: 3960291
doi: 10.1158/1078-0432.CCR-13-0987
Gu Y, Kaufman JL, Bernal L, Torre C, Matulis SM, Harvey RD, et al. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood. 2014;123:3269–76.
pubmed: 24713927
pmcid: 4046434
doi: 10.1182/blood-2013-08-521914
Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, et al. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res. 2012;72:3360–71.
pubmed: 22562464
doi: 10.1158/0008-5472.CAN-12-0388
Jia X, Li C, Li L, Liu X, Zhou L, Zhang W, et al. Neddylation inactivation facilitates FOXO3a nuclear export to suppress estrogen receptor transcription and improve fulvestrant sensitivity. Clin Cancer Res. 2019;25:3658–72.
pubmed: 30833270
doi: 10.1158/1078-0432.CCR-18-2434
Zhou S, Zhao X, Yang Z, Yang R, Chen C, Zhao K, et al. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma. Int J Cancer. 2019;145:763–74.
pubmed: 31044422
Paiva C, Godbersen JC, Berger A, Brown JR, Danilov AV. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents. Cell Death Dis. 2015;6:e1807.
pubmed: 26158513
pmcid: 4650717
doi: 10.1038/cddis.2015.161
Paiva C, Godbersen JC, Rowland T, Danilova OV, Danes C, Berger A, et al. Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis. Oncotarget. 2017;8:21128–39.
pubmed: 28177892
pmcid: 5400571
doi: 10.18632/oncotarget.15050
Best S, Lam V, Liu T, Bruss N, Kittai A, Danilova OV, et al. Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells. Leukemia. 2021;35:156–68.
pubmed: 32203139
doi: 10.1038/s41375-020-0794-0
Petillo S, Capuano C, Molfetta R, Fionda C, Mekhloufi A, Pighi C, et al. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition. Cell Death Dis. 2021;12:836.
pubmed: 34482362
pmcid: 8418610
doi: 10.1038/s41419-021-04104-w
Wang X, Best S, Danilov AV. Neddylation and anti-tumor immunity. Oncotarget. 2021;12:2227–30.
pubmed: 34676055
pmcid: 8522835
doi: 10.18632/oncotarget.28019
Torka P, Kambhampati S, Chen L, Wang X, Chen C, Vuong D, et al. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Blood Cancer J. 2023;13:9.
pubmed: 36631449
pmcid: 9834208
doi: 10.1038/s41408-022-00763-w
Knorr KL, Schneider PA, Meng XW, Dai H, Smith BD, Hess AD, et al. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. Cell Death Differ. 2015;22:2133–42.
pubmed: 26045051
pmcid: 4816118
doi: 10.1038/cdd.2015.74
Torka P, Mavis C, Kothari S, Belliotti S, Gu J, Sundaram S, et al. Pevonedistat, a NEDD8-activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre-clinical models of diffuse large B-cell lymphoma. EJHaem. 2020;1:122–32.
pubmed: 33073261
pmcid: 7566777
doi: 10.1002/jha2.2
Kittai AS, Danilova OV, Lam V, Liu T, Bruss N, Best S, et al. NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells. Oncotarget. 2021;12:2068–74.
pubmed: 34611480
pmcid: 8487718
doi: 10.18632/oncotarget.28063
Wang X, Waschke BC, Woolaver RA, Chen Z, Zhang G, Piscopio AD, et al. Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas. Cancer Immunol Res. 2019;7:1318–31.
pubmed: 31235619
pmcid: 6679731
doi: 10.1158/2326-6066.CIR-18-0875
Song N, Cao C, Tang YM, Bi LY, Jiang Y, Zhou YS, et al. The ubiquitin ligase SCFFBXW7 alpha promotes GATA3 degradation. J Cell Physiol. 2018;233:2366–77.
pubmed: 28722108
doi: 10.1002/jcp.26108
Gibson HM, Mishra A, Chan DV, Hake TS, Porcu P, Wong HK. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sezary syndrome. J Investig Dermatol. 2013;133:249–57.
pubmed: 22951729
doi: 10.1038/jid.2012.265
Palazon A, Tyrakis PA, Macias D, Velica P, Rundqvist H, Fitzpatrick S, et al. An HIF-1 alpha/VEGF-A axis in cytotoxic T cells regulates tumor progression. Cancer Cell. 2017;32:669.
pubmed: 29136509
pmcid: 5691891
doi: 10.1016/j.ccell.2017.10.003
Filippova N, Yang X, An Z, Nabors LB, Pereboeva L. Blocking PD1/PDL1 interactions together with MLN4924 therapy is a potential strategy for glioma treatment. J Cancer Sci Ther. 2018;10:190–7.
pubmed: 30393513
pmcid: 6214201
doi: 10.4172/1948-5956.1000543
Gibson HM, Hedgcock CJ, Aufiero BM, Wilson AJ, Hafner MS, Tsokos GC, et al. Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J Immunol. 2007;179:3831–40.
pubmed: 17785820
doi: 10.4049/jimmunol.179.6.3831
Chen C, Rowell EA, Thomas RM, Hancock WW, Wells AD. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem. 2006;281:36828–34.
pubmed: 17028180
doi: 10.1074/jbc.M608848200
Zhou L, Jiang Y, Luo Q, Li L, Jia L. Neddylation: a novel modulator of the tumor microenvironment. Mol Cancer. 2019;18:77.
pubmed: 30943988
pmcid: 6446326
doi: 10.1186/s12943-019-0979-1
Jin HS, Liao L, Park Y, Liu YC. Neddylation pathway regulates T-cell function by targeting an adaptor protein Shc and a protein kinase Erk signaling. Proc Natl Acad Sci USA. 2013;110:624–9.
pubmed: 23267066
doi: 10.1073/pnas.1213819110
Cheng Q, Liu J, Pei Y, Zhang Y, Zhou D, Pan W, et al. Neddylation contributes to CD4+ T cell-mediated protective immunity against blood-stage Plasmodium infection. PLoS Pathog. 2018;14:e1007440.
pubmed: 30462731
pmcid: 6249024
doi: 10.1371/journal.ppat.1007440
Mathewson ND, Fujiwara H, Wu SR, Toubai T, Oravecz-Wilson K, Sun Y, et al. SAG/Rbx2-dependent neddylation regulates T-cell responses. Am J Pathol. 2016;186:2679–91.
pubmed: 27543965
pmcid: 5222982
doi: 10.1016/j.ajpath.2016.06.014
Friend SF, Peterson LK, Treacy E, Stefanski AL, Sosinowski T, Pennock ND, et al. The discovery of a reciprocal relationship between tyrosine-kinase signaling and cullin neddylation. PLoS ONE. 2013;8:e75200.
pubmed: 24124476
pmcid: 3790728
doi: 10.1371/journal.pone.0075200
Mathewson N, Toubai T, Kapeles S, Sun Y, Oravecz-Wilson K, Tamaki H, et al. Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood. 2013;122:2062–73.
pubmed: 23863900
pmcid: 3778550
doi: 10.1182/blood-2013-02-486373
Zhou L, Jiang Y, Liu X, Li L, Yang X, Dong C, et al. Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-kappaB-CCL2 signaling in lung cancer. Oncogene. 2019;38:5792–804.
pubmed: 31243299
doi: 10.1038/s41388-019-0840-4
Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91–5.
pubmed: 29160310
doi: 10.1038/nature25015
Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Investig. 2018;128:580–8.
pubmed: 29337303
pmcid: 5785245
doi: 10.1172/JCI96061
McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, et al. Proteome instability is a therapeutic vulnerability in mismatch repair-deficient cancer. Cancer Cell. 2020;37:371.
pubmed: 32109374
pmcid: 7337255
doi: 10.1016/j.ccell.2020.01.011
Ioannou N, Hagner PR, Stokes M, Gandhi AK, Apollonio B, Fanous M, et al. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood. 2021;137:216–31.
pubmed: 33024998
pmcid: 7820876
doi: 10.1182/blood.2020006073
Ioannou N, Jain K, Ramsay AG. Immunomodulatory drugs for the treatment of B cell malignancies. Int J Mol Sci. 2021;22:8572.
pubmed: 34445275
pmcid: 8395307
doi: 10.3390/ijms22168572
Yu F, White SB, Zhao Q, Lee FS. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA. 2001;98:9630–5.
pubmed: 11504942
pmcid: 55503
doi: 10.1073/pnas.181341498
Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA. 2000;97:10430–5.
pubmed: 10973499
pmcid: 27041
doi: 10.1073/pnas.190332597
Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2:673–82.
pubmed: 12209156
doi: 10.1038/nrc885